Purpose: The usefulness of 18 F fluorodeoxyglucose (FDG) positron emission tomography (PET) in pediatric Hodgkin lymphoma (p-HL) has been well demonstrated; however, pediatric non-Hodgkin lymphoma (p-NHL) has distinct characteristics from p-HL and adult NHL. We assessed roles of FDG PET in p-NHL. Materials and Methods: Nineteen patients with p-NHL underwent 80 scans. Scans for staging (group A, n = 6) and response assessment (group B, n = 42) were compared with conventional imaging modalities (CIMs). Scans within group B for end-chemotherapy assessment (subgroup B+, n = 11) and for post-therapeutic surveillance (group C, n = 32) were analyzed for diagnostic performance. Results: In group A, PET and CIM demonstrated comparable results. In group B, PET diagnoses were concordant with CIM in 21 and discordant in 11 studies. Of the discordant cases, PET suggested remnant lesions in 5 cases, whereas CIM suggested lesions in 6 cases. PET modified therapeutic strategy in 4 cases by detecting new extranodal lesions. In subgroup B+, sensitivity, specificity, and accuracy for predicting relapse were 50%, 71%, and 64%, respectively. In group C, sensitivity, specificity, and accuracy were 100%, 87%, and 88%, respectively, but positive predictive value was 33%. Conclusions: The role of FDG PET in p-NHL may be limited, unlike with p-HL or adult NHL. Nevertheless, FDG PET may serve complementarily in detecting unexpected lesions that can emerge in p-NHL.
L ymphoma is a common malignant disease in children, and it has a different presentation from lymphoma in adults, especially in non-Hodgkin lymphoma (NHL). The majority of children with NHL have high-grade tumors. The presentation of pediatric NHL (p-NHL) is also different from that of pediatric Hodgkin lymphoma (p-HL). The tendency toward extranodal involvement is common in p-NHL but uncommon in p-HL. 1 Overall survival rate is higher than 90% in p-HL and approximately 70% in p-NHL; however, prognosis is generally poor with relapsed disease in p-NHL, especially in cases with initial intensive multiagent chemotherapy. 2 The utility of 18 F fluorodeoxyglucose (FDG) positron emission tomography (PET) or PET/computed tomography (CT) for children with lymphoma has yet to be sufficiently discussed, as compared with the extensive studies that have proven the considerable utility of FDG PET in adult lymphoma. 3 Recently, several articles have indicated the value of FDG PET or PET/CT for pediatric lymphoma, and reported that disease staging and clinical management could be modified in 10% to 27% of cases. 4Y8 However, in most published studies, the number of patients with p-HL was larger than that of patients with p-NHL. Indeed, p-NHL represents approximately 60% of pediatric lymphomas with p-HL, representing the remainder in the United States. Furthermore, p-HL is much rarer in Asian populations. 9 Therefore, the patient population studied was not entirely representative of the overall incidence of p-HL and p-NHL. The European Network of Pediatric Hodgkin Lymphoma consists of more than 100 treatment centers throughout the European Union, and large-scale multicenter prospective studies about p-HL are under way. 10 In contrast, there are still only a few studies that discuss the role of FDG PET in p-NHL. 11 In their review article, Shankar et al stated that unlike the validated or estimated utility in p-HL, the role of FDG PET may be limited in p-NHL; however, its utility for response assessment has not been settled. 12 Thus, it is considered preferable that the role of FDG PET in p-NHL should be discussed separately from p-HL because of their different clinical manifestations and prognoses. Therefore, we evaluated the performance of FDG PET in p-NHL for initial staging, response assessment during chemotherapy, and surveillance for relapse.
MATERIALS AND METHODS

Patients and Study Design
Between February 2000 and June 2010, 19 patients (4 females and 15 males) aged less than 20 years (range, 2Y18 years; median age at the time of initial study, 10 years) who had histologically confirmed NHL underwent a total of 80 FDG PET (or PET/CT) examinations at our institute. The histologic tumor subtypes were Burkitt lymphoma in 6 patients, diffuse large B-cell lymphoma in 5 patients, lymphoblastic lymphoma in 5 patients, anaplastic large-cell lymphoma in 2 patients, and natural killer/T-cell lymphoma in 1 patient. The stage of disease was evaluated according to the Murphy classification. 13 Patients' profiles including their treatment protocol and their outcome are given in Table 1 . All studies involved daily clinical diagnostic checkups, and written informed consent was obtained from all patients along with their parents as requested by our ethics committee. The examinations were divided into 1 of the following 3 groups, according to the purpose of the PET scan ( Fig. 1 ).
Group A
PET examinations for initial staging were assigned to this group. It included scans acquired after excision biopsy as long as they took place before the commencement of chemotherapy. This group comprised 6 studies in 6 patients. The contribution to staging was assessed through a comparison with conventional imaging modalities (CIMs), such as ultrasonography, CT, or magnetic resonance imaging (MRI).
Group B
PET examinations during or at the completion of chemotherapy were assigned to this group and included scans acquired after any number of cycles of chemotherapy. Examinations acquired during or after salvage therapy were also included. This group comprised 42 studies in 12 patients. Concordance or discordance in comparison with CIM and the influence on treatment plans were surveyed.
We defined a further subgroup, termed ''subgroup B+,'' which consisted only of examinations for response assessment at the time of completion of remission-induction chemotherapy, excluding scans during or after salvage therapy. Subgroup B+ comprised 11 studies in 11 patients. In this subgroup, PET scans were acquired 6 to 46 days (average, 19 days) after completion of the scheduled chemotherapy regimen. Diagnostic performance at predicting relapse was estimated by calculating the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy.
Group C
This group included PET scans acquired for follow-up surveillance for recurrence after the achievement of complete remission 
PET or PET/CT Scanning
The administered dose of FDG was determined in accordance with the revised European Association of Nuclear Medicine pediatric dosage card after 2008. 14 Before the publication date, administered activity concentrations were approximately 6 MBq/kg (0.16 mCi/kg) for 2-dimensional (2D) mode acquisition and approximately 3 MBq/kg (0.08 mCi/kg) for 3-dimensional (3D) mode acquisitions. Patients received intravenous administration of FDG after fasting for at least 4 hours, and whole-body PET images were acquired approximately 50 minutes later.
Eighteen studies were performed using a combined 3D PET/ CT scanner (Discovery ST Elite, GE Healthcare, Waukesha, WI), which integrates a bismuth germinate crystal PET system with a 16-slice multidetector-row CT. Fifty-seven studies were performed using a 2D PET scanner (Advance, GE Healthcare), and the remaining 5 studies were performed using a 3D PET scanner (C-PET plus, ADAC, Philadelphia, PA). The extent of image acquisition was usually from skull to upper thighs. Entire legs and arms were included when involvement was suspected. The need for sedation during acquisition was assessed by experienced pediatric physicians, and undertaken with the agreement of the parents.
Standard of Reference
In the staging of lymphoma, clinical staging as a standard of reference was determined using all imaging modalities, tissue diagnosis, bone marrow biopsy, and cerebrospinal fluid cytology.
For the chemotherapy response assessment and recurrence surveillance cases, all patients underwent regular follow-up for at least 6 months, with the exception of those who died of progressive disease within their follow-up period. The diagnoses of relapse after remission required confirmation by biopsy and histologic examination. However, when tumors did not show remission despite chemotherapy, tumor enlargement at subsequent images was regarded as an evidence of tumor relapse. When there were no abnormal image findings suggesting relapse during their follow-up period, they were considered to be no evidence of recurrent disease. Spontaneous disappearance of FDG uptake at subsequent scan was also considered benign reactive change.
Interpretation and Data Analysis
Interpretation of FDG PET (or PET/CT) images was performed by consensus of at least 2 experienced nuclear medicine physicians, together with all available clinical information such as patients' history, physical examination, chemotherapy protocol, and previous imaging data. Interpretation criteria were determined according to those provided in the consensus guidelines of the Imaging Subcommittee of the International Harmonization Project in Lymphoma. 15 In addition to the consensual criteria, we considered homogeneously increased thymus uptake with bilobed or inverted-''V''shape as an exclusion of positive findings, as such uptake is ordinarily observed physiologically or as thymic rebound after chemotherapy in children and adolescents. Interpretation of CIM images was performed by experienced radiologists, together with all available clinical information. Interpretations were based on morphologic abnormalities and changes.
RESULTS
Group A
The results of initial staging are given in Table 2 . FDG PET did not contribute to up-or downstaging. As summarized in Table 3 , PET staging results were comparable with those by CIM in all studies.
In 2 cases, FDG PET did not result in an accurate staging. Although these cases were both diagnosed as stage III by FDG PET and CIM, the final determined stage was IV as a result of positive bone marrow biopsy in one case and positive cerebrospinal fluid cytology in the other. In the case of bone marrow involvement (patient #5), FDG PET showed diffuse moderate uptake in bone marrow, which was read as equivocal because it was difficult to distinguish tumor involvement from physiological hypermetabolic bone marrow. 
Group B
The judgments about the achievement of remission were concordant with the findings obtained by CIM in 21 studies and were discordant in 11 studies. In the remaining 10 studies, CIM findings were not available. Among the 21 concordant cases, both methods suspected residual tumor in 11 cases, and suggested the achievement of remission in 10 cases. Among the 11 discordant studies, PET alone suspected residual tumor in 5 cases, and in the other 6 cases, PET suggested the achievement of complete remission, despite CIM results that showed a residual lesion ( Fig. 2 ). It was difficult to determine which modality was predominant, but PET results contributed toward the alteration of treatment strategy in 4 cases, as listed in Table 4 : PET detected additional bone involvement after chemotherapy that resulted in additional radiotherapy in 2 cases; PET showed recurrent bone and neural involvement that led to the withdrawal of standard therapy in the other 2 cases (Fig. 3 ). As shown in Table 4 , 2 of these 4 cases were confirmed by biopsy or cytology. The remaining 2 cases (patient #3 each) were not confirmed because she had already experienced recurrence repeatedly by that time. Tumor biopsies just after FDG PET were not held except the aforementioned 2 additional lesions, which also made it difficult to consider which modality was predominant in this group.
Subgroup B+
All 11 patients (patient #1Y4, 8Y14) also underwent CT or MRI as an end-of-chemotherapy assessment. FDG PET showed abnormal uptake in 4 patients. Of these, 1 patient (patient #2), whose PET finding indicated residual abdominal tumor, turned out to be positive by cere-brospinal fluid cytology and to have sciatic nerve involvement afterward. Another patient (patient #13) was found to have new bone involvement in the distal femur, despite the disappearance of the primary abdominal tumor. Both their diseases deteriorated thereafter. In the remaining 2 patients (patient #3, 12), FDG PET showed residual uptake in the primary tumor; however, the tumor remained in remission until the end of their follow-up period. For patient #12, who had a submandibular mass at the beginning of therapy, CT at the end of therapy showed a nonspecific lymph node, indicating that the CIM result was true negative and the PET result was false positive.
FDG PET showed no significant abnormal uptake in 7 patients. Of these, 5 patients (patient #4, 8, 10, 11, 14) maintained remission without relapse. For patient #11, the CT scan showed a small residual tumor in the anterior mediastinum, suggesting that CIM showed a false-positive and PET showed a true-negative result. The remaining 2 patients relapsed afterward, despite PET-negative results. In 1 patient (patient #9), who had lymphoma of thymus, FDG PET at the end of chemotherapy showed only physiological uptake in the thymus, but focal intense uptake superimposed on physiological thymic uptake was observed 8 months later, and the lesion was resected and proven to be in relapse ( Fig. 4) . This patient was also found to have bone marrow involvement, and died as a consequence of the disease 17 months after the end-therapy assessment scan. In the other patient (patient #1), who had central nerve system (CNS) involvement, tumor relapse was discovered in the testis 23 months after the scan.
Thus, all the 4 patients who experienced relapse were confirmed by either histology or cytology in this subgroup. As summarized in Table 5 , the sensitivity, specificity, PPV, NPV, and accuracy of FDG PET for predicting relapse were 50%, 71%, 50%, 71%, and 64%, respectively. CIM showed the same diagnostic performance, although the individual results were not entirely identical.
Group C
Among 32 studies performed, 2 (6.3%) indicated a relapse, both of which were confirmed histologically (patient #1, 9) . PET identified the relapsed lesions in both cases, and there were no cases where PET failed to detect a relapse. There were 4 false-positive results; the lesion was resected and proved to be lymphadenitis in 1 case, and no further accumulation was observed in subsequent studies of the remaining 3 cases. The other 26 studies showed no abnormal uptake and to date no relapse has occurred. Moderate uptake was seen in an area corresponding to the thymus in several studies, but these incidences were regarded as physiological. Taken together, the sensitivity, specificity, PPV, NPV, and accuracy for relapse were 100%, 87%, 33%, 100%, and 88%, respectively, as summarized in Table 6 .
DISCUSSION
FDG PET is acknowledged as being superior to other imaging modalities for the evaluation of malignant lymphoma. However, in the present study for p-NHL, the performance of FDG PET was not as satisfactory as was expected based on previous experiences reported in the literature.
In the present study, when used for initial staging, FDG PET demonstrated no contribution to up-or downstaging compared with CIM. This may be because all patients except one with primary cutaneous lymphoma were in stage III or worse. In p-NHL, unlike p-HL or adult NHL, most patients present at the hospital in an advanced stage and tend to have extensive disease. 2 CIM are usually sufficient to detect such lesions. Depas et al examined the initial staging of 19 pediatric patients (14 with p-HL and 5 with p-NHL) and observed discordance from conventional methods in 3 patients, none of whom had p-NHL. 6 Amthauer et al studied the initial staging of 6 p-NHL patients and reported the detection of additional nodal lesions in half of the patients, but it resulted in the upstaging of only 1 patient. 11 In addition, Murphy stage IV is described as the presence of bone marrow and/or CNS involvement. 13 In the present study, FDG PET did not result in correct upstaging of 2 cases because of undetected microscopic bone marrow and cerebrospinal involvement. Therefore, in p-NHL, our preliminary data suggest that the clinical role of FDG PET for initial staging is limited; furthermore, it appears difficult to justify the omission of bone marrow biopsy and cerebrospinal fluid cytology even when PET shows negative results. Nevertheless, FDG PET may be helpful for correct upstaging, for example, when massive extranodal bone marrow or CNS involvement is also present, as such cases were encountered in the present study for the scans acquired during chemotherapy. When FDG PET was acquired during or at the end of chemotherapy, several results were obtained that were discordant from CIM, contrary to the findings with the initial staging group, in the present study. As for the cases where PET alone indicated negative, the discordance was thought to be influenced by the fact that FDG uptake mainly reflected biologic activity dependent upon glucose metabolism, whereas CIM simply represented morphologic changes. These changes were not synchronous. Decreased FDG uptake often occurs soon after the initiation of chemotherapy and precedes tumor volume reduction. Many studies have demonstrated that FDG PET acquired in ) with T-lymphoblastic lymphoma of thymus. He was regarded as having achieved complete response. The scan for response assessment (A) only showed physiological thymic uptake. However, 8 months later, he underwent FDG PET again for surveillance (B) and was found to have relapse in the thymus. Focal intense uptake superimposed on the physiological uptake was identified. The tumor was resected and relapse was confirmed.
the early cycles of chemotherapy is superior to CT in predicting the effects of therapy. 16 However, Terasawa et al meta-analyzed the prognostic accuracy for interim response assessment and concluded that it was a reliable test for HL but remained unproven for NHL. 17 Therefore, we caution against concluding that the disappearance of FDG uptake represents tumor cell disappearance and a desirable outcome in p-NHL. As for the cases where PET alone indicated positive, the discordance was presumed to be because of several reasons. First, tumor necrosis and inflammation after chemotherapy may be causes of ''false'' positive uptake, although no case was confirmed histopathologically. Riad et al noted that such phenomenon frequently occurred in Burkitt lymphoma, based upon their surgically validated experiences. 18 Second, unexpected relapses were identified as a new ''true'' positive uptake in several cases. It is important to note that more than 90% of p-NHL cases have high-grade tumor and aggressive behavior. 2 Patients with chemotherapy-resistant lymphoma tend toward rapid progressive relapse. 19 FDG PET would be an effective modality for detecting such lesions. We presume that the discordant positive uptake arising from these reasons may be one of the distinct FDG PET imaging characteristics of p-NHL when compared with p-HL. The results of FDG PET for end-of-therapy response assessment in p-NHL may not be considered favorable. From the results, the likelihood ratio was calculated as 1.75. By contrast, in p-HL, Furth et al examined 40 patients, and they reported that the sensitivity, specificity, PPV, NPV, and accuracy of the end-therapy response assessment were 100%, 78%, 25%, 100%, and 79%, respectively, with the likelihood ratio of 4.5. 10 They concluded that in response assessment of p-HL patients, those with a negative PET result would have an excellent prognosis, whereas those with a positive result would have an increased risk for relapse. As compared with their results for p-HL, the present study of p-NHL showed a lower likelihood ratio. The sensitivity and NPV were lower in our population. Relapse of disease occurred even in the PET-negative cases. Mody et al studied 26 patients with p-NHL for end-of-therapy response assessment and reported that among 4 patients with a negative PET result, there were 2 patients who relapsed within 12 months. 20 The present data suggest that the role of FDG PET for end-of-therapy response assessment may be limited, and negative PET results may not necessarily imply a favorable outcome in p-NHL, unlike those in p-HL where several studies have demonstrated the utility of such a finding. The International Harmonization Project provided updated guidelines on the use of PET and stated that it was essential for the post-treatment assessment of diffuse large B-cell lymphoma and HL; however, in pediatric cases, NHL could have different characteristics and distinct histologic subtypes from NHL in adults. 3 For routine surveillance after complete remission, FDG PET is currently not recommended. 3 In p-HL, Levine et al and Meany et al found that PET was sensitive but not specific for post-treatment evaluation with a strong NPV (100%) but poor PPV (11%Y18%). 21, 22 In the present study for surveillance of p-NHL, we also found a low PPV (33%). Several benign conditions such as post-therapeutic inflammation or physiological activities are liable to cause false-positive results in pediatric patients. FDG accumulation into rebound thymic hyperplasia is common among children and adolescents. The accumulation into activated brown adipose tissue can often be observed unless the room temperature is moderately warmed. Conversely, in the present study, PET was of value in identifying relapse in 2 patients and showed excellent sensitivity. Therefore, although the role of FDG PET for surveillance in asymptomatic people remains unsettled, we believe it may provide beneficial information if there are clinical signs of relapse.
Our results suggest several features that distinguish p-NHL from p-HL and from lymphoma in adults. Therefore, we believe the role of FDG PET should also differ. Several drawbacks due to the more aggressive behaviors of p-NHL may reduce the utility of PET for disease staging and response assessment. Several benign conditions that are characteristic in children could also hinder the diagnostic performance of PET. The role of FDG PET in staging for determining more appropriate therapeutic strategy may be somewhat different between p-HL and p-NHL. 12 In p-HL, more detailed and accurate information regarding the spread of involved lesions is required to plan the delivery of radiotherapy, and FDG PET often provides information resulting in correct upstaging. 23 Conversely, in p-NHL where treatment is typically risk-adapted intensive chemotherapy without radiotherapy, the precise localization of every site of small bulk disease is not always necessary to achieve high cure rates. 24 Moreover, for stage IV patients already diagnosed by bone marrow biopsy or cerebrospinal fluid cytology, FDG PET can no longer contribute to either upstaging or the alteration of treatment strategy. For response assessment or surveillance of relapse, we believe the difference of biologic behavior, especially the difference of the aggressiveness between p-HL and p-NHL, would explain our suggestion that FDG might have a more limited role for p-NHL than for p-HL. As Kasamon et al have mentioned, lymphomas are usually not diagnosed until they reach a size of 10 10 to 10 11 cells, and the limit of resolution of FDG PET for the detection of lymphoma generally is a size of approximately 10 8 to 10 9 cells. FDG PET can only measure the first The 2 results were not identical. In one case, CIM showed false-positive but PET showed true-negative. In another one case, CIM showed true-negative but PET showed false-positive.
CIM indicates conventional imaging modalities; PET, positron emission tomography; PPV, Positive predictive value; NPV, Negative predictive value.
2 to 3 log units of tumor cell killing, depending on the initial size of tumor. 25 In short, a negative PET result does not indicate total eradication of disease. Most of p-NHL would have higher aggressiveness than p-HL, and we presume that in p-NHL, even a small amount of tumor cells below the level of the detectability of PET would overcome antitumor immunity. However, we emphasize the ability of PET to identify unexpected lesions, which may occur more frequently in p-NHL, even during therapy. The use of PET could be quite effective in some lesions, such as involvement of peripheral nerves or focal bone marrow involvement, that cannot be easily identified by other imaging modalities.
There exists a trade-off between repeated PET scans, especially PET/CT scans, and lifetime risk of cancer incidence attributable to increasing radiation dose. Many pediatric patients with malignancy tend to undergo repeated scans. Therefore, the reasonable use of the scans is required to avoid unnecessary radiation exposure. Modifying imaging protocols so as to minimize injected FDG activity and CT dose according to patients' size is required.
The present study has several limitations. It was not prospective, and thus our population might contain a bias. Also, the size of the study population was not large. The follow-up periods varied among the patients, and the protocols used for image acquisition and injected dose were not unified because PET studies were performed with 3 different scanners.
In conclusion, FDG PET for p-NHL can sometimes contribute to the determination of more appropriate therapeutic strategies by identifying unexpected lesions; however, its clinical role may not be as promising when compared with the developing consensus about p-HL. Clinicians should make every effort to perform PET/CT scanning properly so as to reasonably reduce the lifetime risk of secondary cancers in pediatric patients. Because p-NHL has considerably distinct clinical characteristics from p-HL, prospective investigations regarding p-NHL cases might be needed to establish the optimal role of FDG PET.
